Development, Optimization and Characterization of Sterically Stabilized Liposomes of Irinotecan
Abstract
The present investigation work summarizes the development of irinotecan liposome injection for intravenous infusion, 4.3 mg/mL (10 mL fill), a generic equivalent of reference product onivyde irinotecan liposome injection for intravenous infusion, 4.3 mg/mL (10 mL fill), which is indicated for colorectal cancer dosing for camptosar. Quality by design (QbD) approach has been used to develop generic irinotecan liposome injection and manufacturing process that ensures the quality, safety and efficacy of irinotecan liposome injection. Preliminary screening trials for drug (API) loading suggest that active loading process with extrusion process using ammonium dihydrogen phosphate shows better drug entrapment with less free drug. A 2(5-1) fractional factorial design of experiments (DoE) adopted to evaluate the effect of lipids concentration in ethanol, hydration temperature, hydration time, extruder temperature and extruder pressure on particle size. Based on design space, optimized process parameters were defined for maintaining the required particle size. A 2(4-1) fractional factorial DoE adopted to evaluate the drug loading heating temperature, drug loading heating time, drug loading cooling temperature and drug loading cooling time on particle size and free drug. Based on design space, optimized process parameters were defined for maintaining the required particle size and % free drug. Stability study of the final formulation suggest no any degradation of impurity and no any % free drug is increasing with respect to stability time. Also all characterization was performed on final formulation and all data is comparable with the reference formulation. The developed formulation of irinotecan liposome injection for intravenous infusion, 4.3 mg/mL (10 mL fill) shows less free and high entrapped drug compared to reference product with new remote loading agent except patent of onivyde.
Keywords:
%Free drug, Cryo-TEM, Fractional factorial Design, Irinotecan, Liposome, Quality by designDOI
https://doi.org/10.25004/IJPSDR.2022.140506References
Ichim CV. Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy. J Transl Med. 2005;3(1):8.
Hua S, Wu SY. The use of lipid-based nanocarriers for targeted pain therapies. Front Pharmacol. 2013;4:143.
Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. DDT. 2003;8:24.
Gabizon A, Goren D, Cohen R, Barenholz Y. Development of liposomal anthracyclines: from basics to clinical applications. J Control Release. 1998;53:275–279.
A l l e n TM. L i p o s ome s . O p p o r t u n i t i e s i n d r u g delivery. Drugs. 1997;54(Suppl 4):8–14.
Himanshu A, Sitasharan P, Singhai AK. Liposomes as drug carriers. IJPLS. 2011;2(7):945–951.
Mayer ID, Madden TM, Bally MU, Cullis PR. In: Liposome Technology. 2. Gregoriadis G, editor. Boca Raton: CRC Press; 1993. pH gradient-mediated drug entrapment in liposomes; pp. 27–44.
Chrai SS, Murari R, Imran A. Liposomes: a review. Bio Pharm. 2001;14(11):10–14.
Andreas W, Karola VU. Liposome technology for industrial purposes. J Drug Deliv. 2011;2011:9.
Atrooz OM. Effects of alkylresorcinolic lipids obtained from acetonic extract of Jordanian wheat grains on liposome properties. Int J Biol Chem. 2011;5(5):314–321.
Benech RO, Kheadr EE, Laridi R, Lacroix C, Fliss I. Inhibition of Listeria innocua in cheddar cheese by addition of nisin Z in liposomes or by in situ production in mixed culture. Applied Environ Microbiol. 2002;68:3683–3690.
Shehata T, Ogawara K, Higaki K, Kimura T. Prolongation of residence time of Liposome by surface-modification with mixture of hydrophilic polymers. Int J Pharm. 2008;359:272–279.
Johnston MJ, Semple SC, Klimuk SK, Ansell S, Maurer N, Cullis PR. Characterization of the drug retention and pharmacokinetic proper t i e s of l iposoma l nanopa r t i c les cont a ining dihydrosphingomyelin. Biochim Biophys Acta. 2007;1768:1121– 1127.
Hofheinz RD, Gnad-Vogt SU, Beyer U, Hochhaus A. Liposomal encapsulated anticancer drugs. Anticancer Drugs. 2005;16:691–707.
Omri A, Suntres ZE, Shek PN. Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Biochem Pharmacol. 2002;64:1407–1413.
Schiffelers RM, Storm G, Bakker-Woudenberg IA. Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue. Pharm Res. 2001;18:780–787.
Stano P, Bufali S, Pisano C, Bucci F, Barbarino M, Santaniello M, Carminati P, Luisi PL. Novel camptothecin analogue (gimatecan)-containing liposomes prepared by the ethanol injection method. J Liposome Res. 2004;14:87–109.
Hemanthkumar M, Spandana V. Liposomal encapsulat ion technology a novel drug delivery system designed for ayurvedic drug preparation. IRJP. 2011;2(10):4–7.
Shaheen SM, Shakil Ahmed FR, Hossen MN, Ahmed M, Amran MS, Ul-Islam MA. Liposome as a carrier for advanced drug delivery. Pak J Biol Sci. 2006;9(6):1181–1191.
Li J, Wang X, Zhang T, Wang C, et al. A review on phospholipids and their main applications in drug delivery systems. Asian J Pharm Sci. 2015;10(2):81–98.
Rieder AA, Koller D, et al. Optimizing rapid solvent exchange preparation of mult ilamellar vesicles. Chem Phys Lipids. 2015;186:39–44.
Bhatia T, Husen P, Brewer J, Bagatolli LA, Hansen PL, Ipsen JH. et al. Preparing giant unilamellar vesicles (GUVs) of complex lipid mixtures on demand: Mixing small unilamellar vesicles of compositionally heterogeneous mixtures. Biochim Biophys Acta. 2015;1848(12):3175–80.
Motta I, Gohlke A, , Li F, Gardavot H, Rothman JE. et al. Formation of giant unilamellar proteo-liposomes by osmotic shock. Langmuir. 2015;31 (25):7091–9.
Karamdad K, Law RV, Seddon JM, Brooks NJ, Ces O. Preparation and mechanical characterisation of giant unilamellar vesicles by a microfluidic method. Lab Chip. 2015;15(2):557–62.
Maria Laura I, Franco D, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006;1(3):297–315.
Holopainen JM, Angelova MI, Soderlund T, Kinnunen PK. Macroscopic consequences of the action of phospholipase c on giant unilamellar liposomes. Biophys J. 2002;83(2):932–43.
Horger KS, Estes DJ, Capone R, Mayer M. Films of agarose enable rapid formation of giant liposomes in solutions of physiologic ionic strength. J Am Chem Soc. 2009;131(5):1810–9.
Morton LA, Saludes JP, Yin H. Constant pressure-controlled extrusion method for the preparation of nano-sized lipid vesicles. J Vis Exp 2012(64):e4151.
Arcadio C, Cullis PR. Recent advances in liposomal drug-delivery systems. Curr Opin Biotechnol. 1995;6:698–708. doi: 10.1016/0958- 1669(95)80115-4.
Gabizon A. In: Drug Carrier Systems. Roerdink FHD, Kron AM, editor. Chichester: Wiley; 1989. Liposomes as a drug delivery system in cancer therapy; pp. 185–211.
Storm G, Roerdink FH, Steerenberg PA, de Jong WH, Crommelin DJA. Influence of lipid composition on the antitumor activity exerted by doxorubicin containing liposomes in a rat solid tumor model. Cancer Res. 1987;47:3366–3372.
Akbarzadeh A, Asgari D, et al. Preparation and in vitro evaluation of doxorubicin-loaded Fe3O4 magnetic nanoparticles modified with biocompatible co-polymers. Int J Nanomedicine. 2012;7:511–526.
Published
Abstract Display: 520 
PDF Downloads: 378 
